Feed AAGH
Summary
64 / 100 · Bulios Score
Valuation 82Growth 100Profitability 40Quality 100Debt 28Stability 10
What speaks for it
- Out of every 100 USD of revenue, 175 USD is left as net profit.
- Revenue grew by 55% a year over the last 3 years.
- It earns 22 USD a year on every 100 USD of invested capital.
- You pay 6.6 USD for 1 USD of yearly profit, little for its sector.
What to watch
- It reports a profit, yet spends more cash than it brings in.
- For every 100 USD of bills due within a year it has 5.6 USD of short-term assets.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapP/E today 6.6
Biotechnology industry median
Today you pay 6.6 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
20212022202320242025
Diluted EPS (USD)
20212022202320242025
Revenue grew by 135% a year over 5 years. Over the last 3 years it grew by 55% a year.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 31 USD
- Sales and administration 174 USD
- Taxes and other -280 USD
- Net profit 175 USD
Net profit, industry median (Biotechnology) -7.3 USD
Out of every 100 USD of revenue, 175 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenCash and short-term investments $29.3K
Debt $3.12M
Free cash flow over 12 months -$352.8K
Over the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.